Frequency of Mutations and Availability of Targeted Therapies in NSCLC.

基因

情形

在非小細胞肺癌(NSCLC)

突變發生佔比

AKT1

Mutation

1%

ALK

Rearrangement

3–7%

BRAF

Mutation

1–3%

DDR2

Mutation

~4%

EGFR

Mutation

10–35%

FGFR1

Amplification

20%

HER2

Mutation

2–4%

KRAS

Mutation

15–25%

MEK1

Mutation

1%

METa

Amplification

2–4%

NRAS

Mutation

1%

PIK3CA

Mutation

1–3%

PTEN

Mutation

4–8%

RET

Rearrangement

1%

ROS1​a

Rearrangement

1%

資料來源:My cancer genome.org

喜歡這篇文章嗎?立即分享

你可能感興趣的文章